Published in Surg Endosc on October 01, 2011
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol (2010) 1.69
Thoracolaparoscopy in the lateral position for esophageal cancer: the experience of a single institution with 112 consecutive patients. Surg Endosc (2010) 1.67
Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol (2009) 1.14
Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J (2010) 1.03
Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg (2009) 0.99
Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc (2008) 0.99
Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics (2010) 0.99
Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med (2010) 0.99
CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol (2009) 0.99
Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc (2008) 0.98
Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg (2009) 0.94
Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices (2010) 0.93
Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn (2010) 0.92
Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn (2010) 0.92
Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol (2009) 0.90
Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn (2010) 0.90
Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther (2010) 0.89
Systems medicine: a real approach for future personalized oncology? Pharmacogenomics (2010) 0.89
Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices (2011) 0.87
From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther (2010) 0.87
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther (2009) 0.86
Isolated tumor cells in breast cancer. N Engl J Med (2009) 0.85
'Big' science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn (2011) 0.83
Total thyroidectomy for the treatment of thyroid diseases in an endemic area. South Med J (2006) 1.46
Laparoscopic ventral hernia repair: pros and cons compared with open hernia repair. JSLS (2008) 1.05
Incisional hernioplasty with extraperitoneal onlay polyester mesh. Am Surg (2004) 1.03
Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg (2009) 0.99
Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther (2006) 0.99
Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn (2010) 0.90
Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc (2008) 0.87
Localized peripancreatic plasma cell Castleman disease. Am J Surg (2010) 0.84
Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer. Int J Biol Markers (2012) 0.84
Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World J Gastroenterol (2012) 0.83
Genomics and challenges toward personalized breast cancer local control. J Clin Oncol (2008) 0.82
Immunohistochemical expression of P15 (INK4B) and SMAD4 in advanced gastric cancer. Anticancer Res (2008) 0.82
High ligation of inferior mesenteric artery: a standard procedure for colorectal cancer? Ann Surg Oncol (2011) 0.81
Short bowel syndrome: current medical and surgical trends. J Clin Gastroenterol (2007) 0.80
A pleomorphic rhabdomyosarcoma mimicking an inguinal hernia: a case report and review of the literature. Case Rep Oncol (2012) 0.78
Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options. Expert Rev Gastroenterol Hepatol (2011) 0.77
EGFR as a Prognostic Marker for Gastric Cancer. World J Surg (2008) 0.77
Translating cancer genomes sequencing revolution into surgical oncology practice. J Surg Res (2010) 0.77
Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. Future Oncol (2011) 0.76
Deep sequencing and integrative genome analysis: approaching a new class of biomarkers and therapeutic targets for breast cancer. Pharmacogenomics (2013) 0.76
Novel next-generation sequencing and networks-based therapeutic targets: realistic and more effective drug design and discovery. Curr Pharm Des (2014) 0.76
Reducing local recurrence after breast-conserving surgery for breast cancer. Ann Surg Oncol (2007) 0.75
Totally laparoscopic total gastrectomy and the challenge of esophagojejunostomy. Surg Endosc (2011) 0.75
Screening for or prevention of local ipsilateral recurrence and contralateral breast cancer after breast-conserving surgery? Ann Surg Oncol (2008) 0.75
Expectations and challenges of laparoscopic total gastrectomy. Surg Endosc (2009) 0.75
Major depression in elderly medical inpatients in Greece, prevalence and identification. Aging Clin Exp Res (2010) 0.75
Can VEGF-D and VEGFR-3 be used as biomarkers for therapeutic decisions in patients with gastric cancer? Nat Clin Pract Oncol (2006) 0.75
Challenges in the treatment of gastroesophageal junction cancer. World J Surg (2011) 0.75
Esophagus and Gastric Cancer: How Surgeon's Experience and Personal Genomics May Improve Locoregional Control and Survival. World J Surg (2009) 0.75
Early signet ring cell or diffuse-type gastric cancer: risks for endoscopic mucosal resection. Ann Surg Oncol (2008) 0.75
Benefits and harms in avoiding axilla lymphadenectomy in breast cancer. Ann Surg Oncol (2008) 0.75
Minimally invasive esophagectomy. Surg Endosc (2010) 0.75
Local control, aggressive surgery, and overall survival for breast cancer. Ann Surg Oncol (2008) 0.75
Does lymphadenectomy improve survival of patients with solid tumors? Ann Surg Oncol (2007) 0.75
Laparoscopic cholecystectomy after open cholecystostomy for gallbladder empyema: a case report. J Laparoendosc Adv Surg Tech A (2007) 0.75
Peritoneal recurrence for gastric cancer: can it be prevented? Ann Surg Oncol (2007) 0.75
Image of the month. Seroma. Arch Surg (2009) 0.75